GenSpera has announced treatment of the first patient with hepatocellular carcinoma (HCC) in its Phase II clinical trial of G-202.
G-202 is expected to have efficacy in a wide variety of tumor types, as it is activated by the enzyme PSMA, which is found at high levels in prostate cancer and the vasculature of almost all solid tumours.
Go deeper with GlobalData
The University of Texas Health Science Center at San Antonio, the Cancer Therapy & Research Center oncologist Dr Devalingam Mahalingam said an advanced HCC patient who has not been helped by standard-of-care therapy with sorafenib was enrolled.
"Often, these patients have limited therapeutic options and survival rates are very modest in this setting," Mahalingam said.
"It is reassuring to know that G-202 provides another therapeutic possibility for our advanced HCC patients in this Phase II clinical study, which follows the safety and therapeutic efficacy we observed in the Phase I clinical study."
G-202 was well-tolerated in the Phase Ib programme in solid tumour patients, and demonstrated prolonged disease stabilisation in several hepatocellular carcinoma patients who had previously progressed on sorafenib therapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
GenSpera CEO and president Dr Craig Dionne said; "The scientific rationale for testing G-202 in HCC is very high and we are pleased with how readily the clinical community has embraced its development for this patient population."
Photo: An intermediate magnification micrograph of hepatocellular carcinoma. Image: Courtesy of Nephron.
